- Home
- Automated
- List of product information
- TAPCOM-S OPHTHALMIC SOLUTION [SIN15060P]
TAPCOM-S OPHTHALMIC SOLUTION [SIN15060P]
Active ingredients: TAPCOM-S OPHTHALMIC SOLUTION
Product Info
TAPCOM-S OPHTHALMIC SOLUTION
[SIN15060P]
Product information
Active Ingredient and Strength | TAFLUPROST - 0.015 MG/ML |
Dosage Form | SOLUTION, STERILE |
Manufacturer and Country | LABORATOIRE UNITHER - FRANCE |
Registration Number | SIN15060P |
Licence Holder | SANTEN PHARMACEUTICAL ASIA PTE. LTD. |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | S01ED51 |
INDICATIONS
Reduction of intraocular pressure (IOP) in adult patients with open angle glaucoma or ocular hypertension who are insufficiently responsive to topical monotherapy with beta-blockers or prostaglandin analogues and require a combination therapy, and who would benefit from preservative free eye drops.
DOSAGE AND ADMINISTRATION
Posology
Recommended therapy is one eye drop in the conjunctival sac of the affected eye(s) once daily.
If one dose is missed, treatment should continue with the next dose as planned. The dose should not exceed one drop in the affected eye(s) daily.
Tapcom-S is a preservative free sterile solution packaged in a single-dose container. For single use only, one container is sufficient to treat both eyes. Any unused solution should be discarded immediately after use.
CONTRAINDICATIONS (This product is contraindicated in the following patients.)
Hypersensitivity to the active substances or to any of the excipients listed in PHARMACEUTICAL PARTICULARS, 1. List of excipients – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.
Reactive airway disease including bronchial asthma, or a history of bronchial asthma, severe chronic obstructive pulmonary disease.
Sinus bradycardia, sick sinus syndrome, including sino-atrial block, second or third degree atrioventricular block not controlled with pace-maker. Overt cardiac failure, cardiogenic shock.
Patients with combination with products containing omidenepag isopropyl.
